Arch Capital Group Ltd. (ACGL)vsDrugs Made In America Acquisition Corp. Ordinary Shares (DMAA)
ACGL
Arch Capital Group Ltd.
$101.81
-0.38%
FINANCIAL SERVICES · Cap: $32.74B
DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares
$10.66
0.00%
FINANCIAL SERVICES · Cap: $258.06M
Smart Verdict
WallStSmart Research — data-driven comparison
ACGL leads profitability with a 24.6% profit margin vs 0.0%. ACGL trades at a lower P/E of 7.2x. ACGL earns a higher WallStSmart Score of 79/100 (B+).
ACGL
Strong Buy79
out of 100
Grade: B+
DMAA
Avoid34
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 94.6% YoY
Every $100 of equity generates 20 in profit
Keeps 25 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Revenue declined 3.3%
Distress zone — elevated risk
0.0% revenue growth
Smaller company, higher risk/reward
ROE of 2.8% — below average capital efficiency
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ACGL
The strongest argument for ACGL centers on P/E Ratio, EPS Growth, Return on Equity. Profitability is solid with margins at 24.6% and operating margin at 25.3%. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bull Case : DMAA
The strongest argument for DMAA centers on Debt/Equity.
Bear Case : ACGL
The primary concerns for ACGL are Revenue Growth, Altman Z-Score.
Bear Case : DMAA
The primary concerns for DMAA are Revenue Growth, Market Cap, Return on Equity. A P/E of 53.1x leaves little room for execution misses.
Key Dynamics to Monitor
ACGL profiles as a declining stock while DMAA is a value play — different risk/reward profiles.
DMAA is growing revenue faster at 0.0% — sustainability is the question.
ACGL generates stronger free cash flow (1.2B), providing more financial flexibility.
Monitor INSURANCE - DIVERSIFIED industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ACGL scores higher overall (79/100 vs 34/100), backed by strong 24.6% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arch Capital Group Ltd.
FINANCIAL SERVICES · INSURANCE - DIVERSIFIED · USA
Arch Capital Group Ltd., offers insurance, reinsurance and mortgage products worldwide. The company is headquartered in Pembroke, Bermuda.
Drugs Made In America Acquisition Corp. Ordinary Shares
FINANCIAL SERVICES · SHELL COMPANIES · USA
Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company aimed at transforming the U.S. pharmaceutical industry by fostering strategic partnerships with innovative healthcare enterprises. With a commitment to enhancing domestic drug production and addressing critical supply chain vulnerabilities, DMAA seeks to ensure the availability of affordable medications for consumers. By leveraging cutting-edge technologies and promoting local manufacturing initiatives, DMAA is well-positioned to play a pivotal role in reshaping the landscape of pharmaceutical access in the United States.
Compare with Other INSURANCE - DIVERSIFIED Stocks
Want to dig deeper into these stocks?